{"protocolSection":{"identificationModule":{"nctId":"NCT05327816","orgStudyIdInfo":{"id":"CR109184"},"secondaryIdInfos":[{"id":"VAC18195RSV1001","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."},{"id":"2022-001015-14","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of Various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"TERMINATED","whyStopped":"Based on recent study data from VAC18193, it was decided to terminate the study. There are no underlying safety concerns to terminate VAC18195RSV1001","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-04-13","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-01-16","type":"ACTUAL"},"completionDateStruct":{"date":"2023-02-14","type":"ACTUAL"},"studyFirstSubmitDate":"2022-04-13","studyFirstSubmitQcDate":"2022-04-13","studyFirstPostDateStruct":{"date":"2022-04-14","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-12-12","resultsFirstSubmitQcDate":"2023-12-12","resultsFirstPostDateStruct":{"date":"2024-01-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-22","lastUpdatePostDateStruct":{"date":"2025-05-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the study is to evaluate safety and immunogenicity of various respiratory syncytial virus (RSV) pre-Fusion (preF)-based vaccine components followed by expanded safety evaluation and durability/revaccination evaluation of the selected RSV preF-based vaccine formulation in participants aged greater than or equal to (\\>=) 60 years in stable health.","detailedDescription":"RSV is an important cause of serious respiratory infections in adults aged 60 years and older. The current study is divided into four cohorts, evaluating various doses and combinations of RSV preF-based vaccines. Cohort 1 will assess the safety and reactogenicity of different RSV preF-based vaccines. Cohort 2 is an expansion of cohort 1 and will assess both safety and immunogenicity of these different RSV vaccines. based on C1 and 2 data the optimal vaccine composition will be selected and further evaluated in Cohort 3 and 4 including durability and revaccination. Cohort 3 will accumulate safety data on the selected vaccine and optimize its formulation. Cohort 4 is an expansion of several arms in cohort 3, aimed to understand the durability of the immune response induced by the selected vaccine, and to explore the possibility for revaccination."},"conditionsModule":{"conditions":["Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":132,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1a: Respiratory Syncytial Virus (RSV) preFusion (preF) Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive single dose of mixture of RSV preF-based vaccine in cohort (C) 1 (Group \\[G\\] 1) and C 2 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 1b: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 1-4) and C 2 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 1c: Placebo","type":"EXPERIMENTAL","description":"Participants will receive single dose of placebo in C 1 (G 1-4) and C 2 through intramuscular injection on Day 1.","interventionNames":["Drug: Placebo"]},{"label":"Arm 2: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 3: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 4: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 5: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 6: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 7: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 3) and C 2 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 8: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 3) and C 2 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 9: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 4) and C 2 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 10: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants will receive a single dose of selected formulation (based on C 1 and 2 results) in C 3 through intramuscular injection on Day 1.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 11a: RSV preF Based Vaccine and Placebo","type":"EXPERIMENTAL","description":"Participants in C 3 will receive a single dose of first vaccination with selected formulation (as per data C1 and 2) plus placebo on Day 1 and re-vaccination with selected formulation whenever revaccination would be needed through intramuscular injection.","interventionNames":["Biological: RSV preF-based Vaccine","Drug: Placebo"]},{"label":"Arm 11b: RSV preF Based Vaccine and Placebo","type":"EXPERIMENTAL","description":"Participants in C 3 will receive a single dose of first vaccination with selected formulation (as per data from C 1 and 2) plus placebo on Day 1 and re-vaccination with placebo whenever revaccination would be needed through intramuscular injection.","interventionNames":["Biological: RSV preF-based Vaccine","Drug: Placebo"]},{"label":"Arm 12: RSV preF Based Vaccine and Placebo","type":"EXPERIMENTAL","description":"Participants in C 3 will receive first vaccination with placebo on Day 1 and re-vaccination with selected formulation (as per data from C 1 and 2) whenever revaccination would be needed through intramuscular injection.","interventionNames":["Biological: RSV preF-based Vaccine","Drug: Placebo"]},{"label":"Arm 13: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants in C 3 will receive the mixture of RSV preF-based vaccine plus placebo on Day 1 through intramuscular injection.","interventionNames":["Biological: RSV preF-based Vaccine","Drug: Placebo"]},{"label":"Arm 14: RSV preF Based Vaccine","type":"EXPERIMENTAL","description":"Participants in C 4 will receive first vaccination with selected formulation (as per data from C 1 and 2) on Day 1 and re-vaccination with selected formulation whenever revaccination would be needed through intramuscular injection.","interventionNames":["Biological: RSV preF-based Vaccine"]},{"label":"Arm 15: RSV preF Based Vaccine and Placebo","type":"EXPERIMENTAL","description":"Participants in C 4 will receive first vaccination with selected formulation (as per data from C 1 and 2) on Day 1 and re-vaccination with placebo whenever revaccination would be needed through intramuscular injection.","interventionNames":["Biological: RSV preF-based Vaccine","Drug: Placebo"]},{"label":"Arm 16: RSV preF Based Vaccine and Placebo","type":"EXPERIMENTAL","description":"Participants in C 4 will receive first vaccination with placebo on Day 1 and re-vaccination with selected formulation (as per data from C 1 and 2) whenever revaccination would be needed through intramuscular injection.","interventionNames":["Biological: RSV preF-based Vaccine","Drug: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"RSV preF-based Vaccine","description":"RSV preF-based vaccine will be administered as intramuscular injection.","armGroupLabels":["Arm 10: RSV preF Based Vaccine","Arm 11a: RSV preF Based Vaccine and Placebo","Arm 11b: RSV preF Based Vaccine and Placebo","Arm 12: RSV preF Based Vaccine and Placebo","Arm 13: RSV preF Based Vaccine","Arm 14: RSV preF Based Vaccine","Arm 15: RSV preF Based Vaccine and Placebo","Arm 16: RSV preF Based Vaccine and Placebo","Arm 1a: Respiratory Syncytial Virus (RSV) preFusion (preF) Based Vaccine","Arm 1b: RSV preF Based Vaccine","Arm 2: RSV preF Based Vaccine","Arm 3: RSV preF Based Vaccine","Arm 4: RSV preF Based Vaccine","Arm 5: RSV preF Based Vaccine","Arm 6: RSV preF Based Vaccine","Arm 7: RSV preF Based Vaccine","Arm 8: RSV preF Based Vaccine","Arm 9: RSV preF Based Vaccine"]},{"type":"DRUG","name":"Placebo","description":"Placebo will be administered as intramuscular injection.","armGroupLabels":["Arm 11a: RSV preF Based Vaccine and Placebo","Arm 11b: RSV preF Based Vaccine and Placebo","Arm 12: RSV preF Based Vaccine and Placebo","Arm 13: RSV preF Based Vaccine","Arm 15: RSV preF Based Vaccine and Placebo","Arm 16: RSV preF Based Vaccine and Placebo","Arm 1c: Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","timeFrame":"From Day 1 up to 6 months post vaccination (up to Day 183)"},{"measure":"Number of Participants With Adverse Events of Special Interest (AESIs)","description":"Number of participants with AESIs were reported. Thrombosis with thrombocytopenia syndrome (TTS) were considered as potential AESIs.","timeFrame":"From Day 1 up to 6 months post vaccination (up to Day 183)"},{"measure":"Number of Participants With Solicited Local and Systemic Adverse Events (AEs)","description":"Number of participants with solicited local and systemic AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, are used to assess the reactogenicity of the study vaccine and are pre-defined local (injection site). Solicited systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).","timeFrame":"7 days post vaccination (Day 8)"},{"measure":"Number of Participants With Unsolicited Adverse Events (AEs)","description":"Number of participants with unsolicited AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs are all AEs for which the participant were not specifically questioned in the participant diary.","timeFrame":"28 days post vaccination (Day 29)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In the investigator's clinical judgment, participant must be in stable health at the time of vaccination. Participants may have underlying illnesses such as hypertension, congestive heart failure, chronic obstructive pulmonary disease (COPD), Type 2 diabetes mellitus, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are stable at the time of vaccination, and these conditions receive routine follow-up by the participant's healthcare provider.\n* Participants will be included on the basis of physical examination, medical history, and vital signs performed between informed consent form (ICF) signature and vaccination\n* For participants in Cohorts 1 and 2 only: Participant must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the laboratory screening tests are outside the laboratory normal reference ranges and additionally within the limits of toxicity Grade 2 according to the United States Food and Drug Administration (US FDA) toxicity tables (that is, for tests in the FDA table), the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator\n* Agrees not to donate blood from the time of vaccination through 3 months after vaccination\n* Must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study\n\nExclusion Criteria:\n\n* History of malignancy within 5 years before screening not in the following categories: a) Participants with squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix may be enrolled at the discretion of the investigator; b) Participants with a history of malignancy within 5 years before screening, with minimal risk of recurrence per investigator's judgment, can be enrolled\n* Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine components\n* Per medical history, participant has chronic active hepatitis B or hepatitis C infection, human immunodeficiency viruses (HIV) type 1 or type 2 infection, acute polyneuropathy (example, Guillain-Barré syndrome) or chronic idiopathic demyelinating polyneuropathy\n* Participant is in receipt of, or planning to receive, licensed live attenuated vaccine within 28 days before and after study vaccinations; other licensed vaccines (that is, not live such as, influenza, tetanus, hepatitis A or B, rabies) within 14 days before and after study vaccinations\n* Received treatment with immunoglobulins expected to impact the vaccine-induced immune response (including monoclonal antibodies \\[MAbs\\] for chronic underlying conditions) in the 2 months; immunoglobulins specific to respiratory syncytial virus (RSV), human metapneumovirus, or parainfluenza viruses in the 12 months; apheresis therapies in the 4 months; or blood products in the 4 months prior to study vaccination or has any plans to receive such treatment during the study","healthyVolunteers":true,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Ark Clinical Research","city":"Long Beach","state":"California","zip":"90815","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Accel Research Sites","city":"DeLand","state":"Florida","zip":"32720","country":"United States","geoPoint":{"lat":29.02832,"lon":-81.30312}},{"facility":"Floridian Clinical Research LLC","city":"Miami Lakes","state":"Florida","zip":"33016","country":"United States","geoPoint":{"lat":25.90871,"lon":-80.30866}},{"facility":"Heartland Research Associates, an AMR Company","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Clinical Trials Management, LLC","city":"Metairie","state":"Louisiana","zip":"70006","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"facility":"The Center for Pharmaceutical Research (CPR)","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"CTI Clinical Trial and Consulting Services","city":"Cincinnati","state":"Ohio","zip":"45212","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Meridian Clinical Research, LLC","city":"Cincinnati","state":"Ohio","zip":"45246","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Coastal Carolina Research Center","city":"North Charleston","state":"South Carolina","zip":"29405","country":"United States","geoPoint":{"lat":32.85462,"lon":-79.97481}},{"facility":"AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company","city":"Knoxville","state":"Tennessee","zip":"37920","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Tekton Research Inc.","city":"Austin","state":"Texas","zip":"78745","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu","url":"https://www.janssen.com/clinical-trials/transparency"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Study was terminated on sponsor's decision, hence, participants were enrolled in Cohort 1 only. Cohorts 2, 3, and 4 were not initiated. Participants enrolled in Cohort 1 completed visit up to Day 183 (6-months post vaccination) and safety evaluations were performed only for Cohort 1. Since the study was terminated prior to Cohort 2 enrolment and the data was planned for combined Cohorts 1 and 2, samples collected in Cohort 1 alone were not tested and no immunogenicity testing was performed.","groups":[{"id":"FG000","title":"Arm 1a (Cohort 1): Ad26.RSV-B.PreF2 1*10^11 vp + RSV-B.PreF Protein 150 mcg","description":"Participants received single intramuscular (IM) injections of adenovirus serotype 26 respiratory syncytial virus-B prefusion-F2 protein (Ad26.RSV-B.preF2) 1\\*10\\^11 viral particles (vp) and RSV-B.preF protein 150 micrograms (mcg) on Day 1."},{"id":"FG001","title":"Arm 1b (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 150 mcg","description":"Participants received single IM injections of adenovirus serotype 26 respiratory syncytial virus-A prefusion-F protein (Ad26.RSV-A.preF) 1\\*10\\^11 vp and RSV-A.preF protein 150 mcg on Day 1."},{"id":"FG002","title":"Arm 1c (Cohort 1): Pooled Placebo","description":"Participants received a single IM injection of placebo on Day 1."},{"id":"FG003","title":"Arm 2 (Cohort 1): RSV-A.PreF Protein 150 mcg + RSV-B.PreF Protein 150 mcg","description":"Participants received single IM injections of RSV-A.preF protein 150 mcg and RSV-B.preF protein 150 mcg on Day 1."},{"id":"FG004","title":"Arm 3 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 2.5*10^10 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 2.5\\*10\\^10 vp, Ad26.RSV-B.preF2 2.5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"FG005","title":"Arm 4 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 5*10^10 vp + RSV-A.PreF /RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 5\\*10\\^10 vp, Ad26.RSV-B.preF2 5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"FG006","title":"Arm 5 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"FG007","title":"Arm 6 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF and RSV-B.PreF at 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"FG008","title":"Arm 7 (Cohort 1):Ad26.RSV-A.PreF 1*10^11vp/Ad26.RSV-B.preF2 5*10^10vp + RSV-A.Pre/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 5\\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"FG009","title":"Arm 8 (Cohort 1): Ad26.RSV-A.PreF 1.5*10^11 vp +RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1.5\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"FG010","title":"Arm 9 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 1*10^11 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"12"},{"groupId":"FG009","numSubjects":"12"},{"groupId":"FG010","numSubjects":"12"}]},{"type":"Treated (Full Analysis Set)","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"11"},{"groupId":"FG007","numSubjects":"11"},{"groupId":"FG008","numSubjects":"11"},{"groupId":"FG009","numSubjects":"12"},{"groupId":"FG010","numSubjects":"12"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"12"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"12"},{"groupId":"FG009","numSubjects":"12"},{"groupId":"FG010","numSubjects":"12"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]},{"type":"Study Terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"11"},{"groupId":"FG006","numSubjects":"11"},{"groupId":"FG007","numSubjects":"11"},{"groupId":"FG008","numSubjects":"11"},{"groupId":"FG009","numSubjects":"11"},{"groupId":"FG010","numSubjects":"12"}]},{"type":"Randomized but not treated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The full analysis set (FAS) included all participants who received the study vaccine, regardless of the occurrence of protocol deviations.","groups":[{"id":"BG000","title":"Arm 1a (Cohort 1): Ad26.RSV-B.PreF2 1*10^11 vp + RSV-B.PreF Protein 150 mcg","description":"Participants received single intramuscular (IM) injections of adenovirus serotype 26 respiratory syncytial virus-B prefusion-F2 protein (Ad26.RSV-B.preF2) 1\\*10\\^11 viral particles (vp) and RSV-B.preF protein 150 micrograms (mcg) on Day 1."},{"id":"BG001","title":"Arm 1b (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 150 mcg","description":"Participants received single IM injections of adenovirus serotype 26 respiratory syncytial virus-A prefusion-F protein (Ad26.RSV-A.preF) 1\\*10\\^11 vp and RSV-A.preF protein 150 mcg on Day 1."},{"id":"BG002","title":"Arm 1c (Cohort 1): Pooled Placebo","description":"Participants received a single IM injection of placebo on Day 1."},{"id":"BG003","title":"Arm 2 (Cohort 1): RSV-A.PreF Protein 150 mcg + RSV-B.PreF Protein 150 mcg","description":"Participants received single IM injections of RSV-A.preF protein 150 mcg and RSV-B.preF protein 150 mcg on Day 1."},{"id":"BG004","title":"Arm 3 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 2.5*10^10 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 2.5\\*10\\^10 vp, Ad26.RSV-B.preF2 2.5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"BG005","title":"Arm 4 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 5*10^10 vp + RSV-A.PreF /RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 5\\*10\\^10 vp, Ad26.RSV-B.preF2 5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"BG006","title":"Arm 5 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"BG007","title":"Arm 6 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF and RSV-B.PreF at 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"BG008","title":"Arm 7 (Cohort 1):Ad26.RSV-A.PreF 1*10^11vp/Ad26.RSV-B.preF2 5*10^10vp + RSV-A.Pre/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 5\\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"BG009","title":"Arm 8 (Cohort 1): Ad26.RSV-A.PreF 1.5*10^11 vp +RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1.5\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"BG010","title":"Arm 9 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 1*10^11 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"BG011","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"11"},{"groupId":"BG008","value":"11"},{"groupId":"BG009","value":"12"},{"groupId":"BG010","value":"12"},{"groupId":"BG011","value":"129"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69.1","spread":"5.42"},{"groupId":"BG001","value":"67.8","spread":"5.01"},{"groupId":"BG002","value":"66.2","spread":"5.65"},{"groupId":"BG003","value":"69.3","spread":"3.39"},{"groupId":"BG004","value":"65.7","spread":"4.94"},{"groupId":"BG005","value":"67.4","spread":"4.83"},{"groupId":"BG006","value":"68.5","spread":"6.12"},{"groupId":"BG007","value":"64.8","spread":"4.14"},{"groupId":"BG008","value":"66.3","spread":"3.04"},{"groupId":"BG009","value":"65.4","spread":"4.4"},{"groupId":"BG010","value":"65.5","spread":"3.78"},{"groupId":"BG011","value":"66.9","spread":"4.76"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"7"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"77"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"7"},{"groupId":"BG011","value":"52"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"7"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"11"},{"groupId":"BG009","value":"11"},{"groupId":"BG010","value":"10"},{"groupId":"BG011","value":"122"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"18"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"10"},{"groupId":"BG009","value":"10"},{"groupId":"BG010","value":"10"},{"groupId":"BG011","value":"109"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"UNITED STATES","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"11"},{"groupId":"BG008","value":"11"},{"groupId":"BG009","value":"12"},{"groupId":"BG010","value":"12"},{"groupId":"BG011","value":"129"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.","populationDescription":"The full analysis set (FAS) included all participants who received the study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to 6 months post vaccination (up to Day 183)","groups":[{"id":"OG000","title":"Arm 1a (Cohort 1): Ad26.RSV-B.PreF2 1*10^11 vp + RSV-B.PreF Protein 150 mcg","description":"Participants received single intramuscular (IM) injections of adenovirus serotype 26 respiratory syncytial virus-B prefusion-F2 protein (Ad26.RSV-B.preF2) 1\\*10\\^11 viral particles (vp) and RSV-B.preF protein 150 micrograms (mcg) on Day 1."},{"id":"OG001","title":"Arm 1b (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 150 mcg","description":"Participants received single IM injections of adenovirus serotype 26 respiratory syncytial virus-A prefusion-F protein (Ad26.RSV-A.preF) 1\\*10\\^11 vp and RSV-A.preF protein 150 mcg on Day 1."},{"id":"OG002","title":"Arm 1c (Cohort 1): Pooled Placebo","description":"Participants received a single IM injection of placebo on Day 1."},{"id":"OG003","title":"Arm 2 (Cohort 1): RSV-A.PreF Protein 150 mcg + RSV-B.PreF Protein 150 mcg","description":"Participants received single IM injections of RSV-A.preF protein 150 mcg and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG004","title":"Arm 3 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 2.5*10^10 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 2.5\\*10\\^10 vp, Ad26.RSV-B.preF2 2.5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG005","title":"Arm 4 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 5*10^10 vp + RSV-A.PreF /RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 5\\*10\\^10 vp, Ad26.RSV-B.preF2 5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG006","title":"Arm 5 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"OG007","title":"Arm 6 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF and RSV-B.PreF at 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG008","title":"Arm 7 (Cohort 1):Ad26.RSV-A.PreF 1*10^11vp/Ad26.RSV-B.preF2 5*10^10vp + RSV-A.Pre/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 5\\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG009","title":"Arm 8 (Cohort 1): Ad26.RSV-A.PreF 1.5*10^11 vp +RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1.5\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"OG010","title":"Arm 9 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 1*10^11 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"11"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events of Special Interest (AESIs)","description":"Number of participants with AESIs were reported. Thrombosis with thrombocytopenia syndrome (TTS) were considered as potential AESIs.","populationDescription":"The FAS included all participants who received the study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 up to 6 months post vaccination (up to Day 183)","groups":[{"id":"OG000","title":"Arm 1a (Cohort 1): Ad26.RSV-B.PreF2 1*10^11 vp + RSV-B.PreF Protein 150 mcg","description":"Participants received single intramuscular (IM) injections of adenovirus serotype 26 respiratory syncytial virus-B prefusion-F2 protein (Ad26.RSV-B.preF2) 1\\*10\\^11 viral particles (vp) and RSV-B.preF protein 150 micrograms (mcg) on Day 1."},{"id":"OG001","title":"Arm 1b (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 150 mcg","description":"Participants received single IM injections of adenovirus serotype 26 respiratory syncytial virus-A prefusion-F protein (Ad26.RSV-A.preF) 1\\*10\\^11 vp and RSV-A.preF protein 150 mcg on Day 1."},{"id":"OG002","title":"Arm 1c (Cohort 1): Pooled Placebo","description":"Participants received a single IM injection of placebo on Day 1."},{"id":"OG003","title":"Arm 2 (Cohort 1): RSV-A.PreF Protein 150 mcg + RSV-B.PreF Protein 150 mcg","description":"Participants received single IM injections of RSV-A.preF protein 150 mcg and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG004","title":"Arm 3 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 2.5*10^10 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 2.5\\*10\\^10 vp, Ad26.RSV-B.preF2 2.5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG005","title":"Arm 4 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 5*10^10 vp + RSV-A.PreF /RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 5\\*10\\^10 vp, Ad26.RSV-B.preF2 5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG006","title":"Arm 5 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"OG007","title":"Arm 6 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF and RSV-B.PreF at 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG008","title":"Arm 7 (Cohort 1):Ad26.RSV-A.PreF 1*10^11vp/Ad26.RSV-B.preF2 5*10^10vp + RSV-A.Pre/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 5\\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG009","title":"Arm 8 (Cohort 1): Ad26.RSV-A.PreF 1.5*10^11 vp +RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1.5\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"OG010","title":"Arm 9 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 1*10^11 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"11"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Local and Systemic Adverse Events (AEs)","description":"Number of participants with solicited local and systemic AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs that included injection site pain/tenderness, erythema and swelling at the study vaccine injection site, are used to assess the reactogenicity of the study vaccine and are pre-defined local (injection site). Solicited systemic events included events such as fatigue, headache, nausea, and myalgia, for which participants were specifically questioned and which were noted by participants in their participant diary for 7 days post vaccination (day of vaccination and the subsequent 7 days).","populationDescription":"The FAS included all participants who received the study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post vaccination (Day 8)","groups":[{"id":"OG000","title":"Arm 1a (Cohort 1): Ad26.RSV-B.PreF2 1*10^11 vp + RSV-B.PreF Protein 150 mcg","description":"Participants received single intramuscular (IM) injections of adenovirus serotype 26 respiratory syncytial virus-B prefusion-F2 protein (Ad26.RSV-B.preF2) 1\\*10\\^11 viral particles (vp) and RSV-B.preF protein 150 micrograms (mcg) on Day 1."},{"id":"OG001","title":"Arm 1b (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 150 mcg","description":"Participants received single IM injections of adenovirus serotype 26 respiratory syncytial virus-A prefusion-F protein (Ad26.RSV-A.preF) 1\\*10\\^11 vp and RSV-A.preF protein 150 mcg on Day 1."},{"id":"OG002","title":"Arm 1c (Cohort 1): Pooled Placebo","description":"Participants received a single IM injection of placebo on Day 1."},{"id":"OG003","title":"Arm 2 (Cohort 1): RSV-A.PreF Protein 150 mcg + RSV-B.PreF Protein 150 mcg","description":"Participants received single IM injections of RSV-A.preF protein 150 mcg and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG004","title":"Arm 3 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 2.5*10^10 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 2.5\\*10\\^10 vp, Ad26.RSV-B.preF2 2.5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG005","title":"Arm 4 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 5*10^10 vp + RSV-A.PreF /RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 5\\*10\\^10 vp, Ad26.RSV-B.preF2 5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG006","title":"Arm 5 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"OG007","title":"Arm 6 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF and RSV-B.PreF at 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG008","title":"Arm 7 (Cohort 1):Ad26.RSV-A.PreF 1*10^11vp/Ad26.RSV-B.preF2 5*10^10vp + RSV-A.Pre/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 5\\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG009","title":"Arm 8 (Cohort 1): Ad26.RSV-A.PreF 1.5*10^11 vp +RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1.5\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"OG010","title":"Arm 9 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 1*10^11 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"11"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"12"}]}],"classes":[{"title":"Solicited Local AEs","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"7"}]}]},{"title":"Solicited Systemic AEs","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"7"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited Adverse Events (AEs)","description":"Number of participants with unsolicited AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs are all AEs for which the participant were not specifically questioned in the participant diary.","populationDescription":"The FAS included all participants who received the study vaccine, regardless of the occurrence of protocol deviations.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"28 days post vaccination (Day 29)","groups":[{"id":"OG000","title":"Arm 1a (Cohort 1): Ad26.RSV-B.PreF2 1*10^11 vp + RSV-B.PreF Protein 150 mcg","description":"Participants received single intramuscular (IM) injections of adenovirus serotype 26 respiratory syncytial virus-B prefusion-F2 protein (Ad26.RSV-B.preF2) 1\\*10\\^11 viral particles (vp) and RSV-B.preF protein 150 micrograms (mcg) on Day 1."},{"id":"OG001","title":"Arm 1b (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 150 mcg","description":"Participants received single IM injections of adenovirus serotype 26 respiratory syncytial virus-A prefusion-F protein (Ad26.RSV-A.preF) 1\\*10\\^11 vp and RSV-A.preF protein 150 mcg on Day 1."},{"id":"OG002","title":"Arm 1c (Cohort 1): Pooled Placebo","description":"Participants received a single IM injection of placebo on Day 1."},{"id":"OG003","title":"Arm 2 (Cohort 1): RSV-A.PreF Protein 150 mcg + RSV-B.PreF Protein 150 mcg","description":"Participants received single IM injections of RSV-A.preF protein 150 mcg and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG004","title":"Arm 3 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 2.5*10^10 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 2.5\\*10\\^10 vp, Ad26.RSV-B.preF2 2.5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG005","title":"Arm 4 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 5*10^10 vp + RSV-A.PreF /RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 5\\*10\\^10 vp, Ad26.RSV-B.preF2 5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG006","title":"Arm 5 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"OG007","title":"Arm 6 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF and RSV-B.PreF at 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG008","title":"Arm 7 (Cohort 1):Ad26.RSV-A.PreF 1*10^11vp/Ad26.RSV-B.preF2 5*10^10vp + RSV-A.Pre/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 5\\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."},{"id":"OG009","title":"Arm 8 (Cohort 1): Ad26.RSV-A.PreF 1.5*10^11 vp +RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1.5\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1."},{"id":"OG010","title":"Arm 9 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 1*10^11 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"11"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"5"},{"groupId":"OG010","value":"2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"From Day 1 up to 6 months post vaccination (up to Day 183)","description":"The full analysis set (FAS) included all participants who received the study vaccine, regardless of the occurrence of protocol deviations.","eventGroups":[{"id":"EG000","title":"Arm 1a (Cohort 1): Ad26.RSV-B.PreF2 1*10^11 vp + RSV-B.PreF Protein 150 mcg","description":"Participants received single intramuscular (IM) injections of adenovirus serotype 26 respiratory syncytial virus-B prefusion-F2 protein (Ad26.RSV-B.preF2) 1\\*10\\^11 viral particles (vp) and RSV-B.preF protein 150 micrograms (mcg) on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG001","title":"Arm 1b (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 150 mcg","description":"Participants received single IM injections of adenovirus serotype 26 respiratory syncytial virus-A prefusion-F protein (Ad26.RSV-A.preF) 1\\*10\\^11 vp and RSV-A.preF protein 150 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":9,"otherNumAtRisk":12},{"id":"EG002","title":"Arm 1c (Cohort 1): Pooled Placebo","description":"Participants received a single IM injection of placebo on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":1,"seriousNumAtRisk":12,"otherNumAffected":10,"otherNumAtRisk":12},{"id":"EG003","title":"Arm 2 (Cohort 1): RSV-A.PreF Protein 150 mcg + RSV-B.PreF Protein 150 mcg","description":"Participants received single IM injections of RSV-A.preF protein 150 mcg and RSV-B.preF protein 150 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":1,"seriousNumAtRisk":12,"otherNumAffected":10,"otherNumAtRisk":12},{"id":"EG004","title":"Arm 3 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 2.5*10^10 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 2.5\\*10\\^10 vp, Ad26.RSV-B.preF2 2.5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":10,"otherNumAtRisk":12},{"id":"EG005","title":"Arm 4 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 5*10^10 vp + RSV-A.PreF /RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 5\\*10\\^10 vp, Ad26.RSV-B.preF2 5 \\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG006","title":"Arm 5 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":11,"seriousNumAffected":1,"seriousNumAtRisk":11,"otherNumAffected":8,"otherNumAtRisk":11},{"id":"EG007","title":"Arm 6 (Cohort 1): Ad26.RSV-A.PreF 1*10^11 vp + RSV-A.PreF and RSV-B.PreF at 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":11,"seriousNumAffected":1,"seriousNumAtRisk":11,"otherNumAffected":11,"otherNumAtRisk":11},{"id":"EG008","title":"Arm 7 (Cohort 1):Ad26.RSV-A.PreF 1*10^11vp/Ad26.RSV-B.preF2 5*10^10vp + RSV-A.Pre/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 5\\*10\\^10 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":11,"seriousNumAffected":1,"seriousNumAtRisk":11,"otherNumAffected":10,"otherNumAtRisk":11},{"id":"EG009","title":"Arm 8 (Cohort 1): Ad26.RSV-A.PreF 1.5*10^11 vp +RSV-A.PreF Protein 300 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1.5\\*10\\^11 vp and RSV-A.preF protein 300 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG010","title":"Arm 9 (Cohort 1): Ad26.RSV-A.PreF/Ad26.RSV-B.preF2 1*10^11 vp + RSV-A.PreF/RSV-B.PreF 150 mcg","description":"Participants received single IM injections of Ad26.RSV-A.preF 1\\*10\\^11 vp, Ad26.RSV-B.preF2 1\\*10\\^11 vp, RSV-A.preF protein 150 mcg, and RSV-B.preF protein 150 mcg on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":8,"otherNumAtRisk":12}],"seriousEvents":[{"term":"Coronary Artery Disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":1,"numAtRisk":11},{"groupId":"EG007","numAffected":1,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Subdural Haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Breast Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":1,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":1,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]}],"otherEvents":[{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":1,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":1,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":12}]},{"term":"Hypoaesthesia Oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":12},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":12},{"groupId":"EG005","numAffected":3,"numAtRisk":12},{"groupId":"EG006","numAffected":4,"numAtRisk":11},{"groupId":"EG007","numAffected":3,"numAtRisk":11},{"groupId":"EG008","numAffected":3,"numAtRisk":11},{"groupId":"EG009","numAffected":4,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":12}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":12}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":1,"numAtRisk":11},{"groupId":"EG009","numAffected":5,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":12}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":12},{"groupId":"EG001","numAffected":7,"numAtRisk":12},{"groupId":"EG002","numAffected":6,"numAtRisk":12},{"groupId":"EG003","numAffected":5,"numAtRisk":12},{"groupId":"EG004","numAffected":7,"numAtRisk":12},{"groupId":"EG005","numAffected":8,"numAtRisk":12},{"groupId":"EG006","numAffected":5,"numAtRisk":11},{"groupId":"EG007","numAffected":9,"numAtRisk":11},{"groupId":"EG008","numAffected":8,"numAtRisk":11},{"groupId":"EG009","numAffected":10,"numAtRisk":12},{"groupId":"EG010","numAffected":7,"numAtRisk":12}]},{"term":"Injection Site Bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":1,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":12},{"groupId":"EG005","numAffected":3,"numAtRisk":12},{"groupId":"EG006","numAffected":2,"numAtRisk":11},{"groupId":"EG007","numAffected":1,"numAtRisk":11},{"groupId":"EG008","numAffected":5,"numAtRisk":11},{"groupId":"EG009","numAffected":3,"numAtRisk":12},{"groupId":"EG010","numAffected":2,"numAtRisk":12}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":1,"numAtRisk":12},{"groupId":"EG006","numAffected":1,"numAtRisk":11},{"groupId":"EG007","numAffected":1,"numAtRisk":11},{"groupId":"EG008","numAffected":1,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Tenderness","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":12},{"groupId":"EG001","numAffected":8,"numAtRisk":12},{"groupId":"EG002","numAffected":5,"numAtRisk":12},{"groupId":"EG003","numAffected":7,"numAtRisk":12},{"groupId":"EG004","numAffected":8,"numAtRisk":12},{"groupId":"EG005","numAffected":10,"numAtRisk":12},{"groupId":"EG006","numAffected":7,"numAtRisk":11},{"groupId":"EG007","numAffected":8,"numAtRisk":11},{"groupId":"EG008","numAffected":9,"numAtRisk":11},{"groupId":"EG009","numAffected":11,"numAtRisk":12},{"groupId":"EG010","numAffected":7,"numAtRisk":12}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":1,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Tinea Pedis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Blood Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":1,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Blood Urea Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Haemoglobin Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":1,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Neutrophil Count Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":1,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":12},{"groupId":"EG001","numAffected":7,"numAtRisk":12},{"groupId":"EG002","numAffected":4,"numAtRisk":12},{"groupId":"EG003","numAffected":6,"numAtRisk":12},{"groupId":"EG004","numAffected":8,"numAtRisk":12},{"groupId":"EG005","numAffected":8,"numAtRisk":12},{"groupId":"EG006","numAffected":6,"numAtRisk":11},{"groupId":"EG007","numAffected":9,"numAtRisk":11},{"groupId":"EG008","numAffected":8,"numAtRisk":11},{"groupId":"EG009","numAffected":9,"numAtRisk":12},{"groupId":"EG010","numAffected":6,"numAtRisk":12}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":12},{"groupId":"EG001","numAffected":6,"numAtRisk":12},{"groupId":"EG002","numAffected":5,"numAtRisk":12},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":12},{"groupId":"EG005","numAffected":4,"numAtRisk":12},{"groupId":"EG006","numAffected":6,"numAtRisk":11},{"groupId":"EG007","numAffected":8,"numAtRisk":11},{"groupId":"EG008","numAffected":8,"numAtRisk":11},{"groupId":"EG009","numAffected":7,"numAtRisk":12},{"groupId":"EG010","numAffected":3,"numAtRisk":12}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Nasal Congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Oropharyngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":12},{"groupId":"EG005","numAffected":2,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":1,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Night Sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":12},{"groupId":"EG006","numAffected":0,"numAtRisk":11},{"groupId":"EG007","numAffected":0,"numAtRisk":11},{"groupId":"EG008","numAffected":0,"numAtRisk":11},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":12}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Study was terminated on sponsor's decision, hence, participants were enrolled in Cohort 1 only. Cohorts 2, 3, and 4 were not initiated. Participants enrolled in Cohort 1 completed visit up to Day 183 (6-months post vaccination) and safety evaluations were performed only for Cohort 1. Since the study was terminated prior to Cohort 2 enrolment and the data was planned for combined Cohorts 1 and 2, samples collected in Cohort 1 alone were not tested and no immunogenicity testing was performed."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application."},"pointOfContact":{"title":"Medical Leader","organization":"Janssen Vaccines & Prevention B.V.","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-12-22","uploadDate":"2023-12-12T06:02","filename":"Prot_000.pdf","size":2767532},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-06-23","uploadDate":"2023-12-12T06:02","filename":"SAP_001.pdf","size":837009}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Belgium","Spain","United Kingdom"]}},"hasResults":true}